{
    "2018-04-17": [
        [
            {
                "time": "2018-04-05",
                "original_text": "Biotech IPOs to Watch in April",
                "features": {
                    "keywords": [
                        "IPOs",
                        "Biotech",
                        "April"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false"
                }
            },
            {
                "time": "2018-04-10",
                "original_text": "Glaxo, Novartis Join $4 Billion Gates-Led Push to Fight Malaria",
                "features": {
                    "keywords": [
                        "Glaxo",
                        "Novartis",
                        "Gates",
                        "Malaria"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false"
                }
            },
            {
                "time": "2018-05-02",
                "original_text": "Novartis’s Innovative Medicines Segment in 1Q18",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Innovative Medicines",
                        "1Q18"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-05-03",
                "original_text": "What's in Store for Novartis (NVS) This Earnings Season?",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Earnings",
                        "Season"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-05-04",
                "original_text": "Novartis’s 1Q18: Analysts Expect Revenue Growth",
                "features": {
                    "keywords": [
                        "Novartis",
                        "1Q18",
                        "Revenue Growth"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-05-05",
                "original_text": "Expectations from Novartis’s 1Q18 Earnings",
                "features": {
                    "keywords": [
                        "Novartis",
                        "1Q18",
                        "Earnings"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-05-10",
                "original_text": "Risankizumab Could Be AbbVie’s Long-Term Growth Driver",
                "features": {
                    "keywords": [
                        "Risankizumab",
                        "AbbVie",
                        "Growth Driver"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false"
                }
            },
            {
                "time": "2018-04-15",
                "original_text": "The Swiss Stock Market Rebounded As Syria Concerns Relax",
                "features": {
                    "keywords": [
                        "Swiss Stock Market",
                        "Syria",
                        "Rebounded"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "general market"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false"
                }
            },
            {
                "time": "2018-05-12",
                "original_text": "Novartis tender offer for AveXis commences",
                "features": {
                    "keywords": [
                        "Novartis",
                        "AveXis",
                        "Tender Offer"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-05-13",
                "original_text": "Novartis Unit Commences Tender Offer For AveXis Stock - Quick Facts",
                "features": {
                    "keywords": [
                        "Novartis",
                        "AveXis",
                        "Tender Offer"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}